|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 453/00 | (2006.01) |
| A61K 31/439 | (2006.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61P 3/00 | (2006.01) |
| (11) | Number of the document | 2970250 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14718854.4 |
| Date of filing the European patent application | 2014-03-14 | |
| (97) | Date of publication of the European application | 2016-01-20 |
| (45) | Date of publication and mention of the grant of the patent | 2021-04-21 |
| (46) | Date of publication of the claims translation | 2021-05-10 |
| (86) | Number | PCT/US2014/027081 |
| Date | 2014-03-14 |
| (87) | Number | WO 2014/152215 |
| Date | 2014-09-25 |
| (30) | Number | Date | Country code |
| 201361791706 P | 2013-03-15 | US |
| (72) |
SIEGEL, Craig, US
ZHAO, Jin, US
|
| (73) |
Genzyme Corporation,
50 Binney Street, Cambridge, MA 02142,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | (S)-Chinuklidin-3-il (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)karbamato druskos formos |
| SALT FORMS OF (S)-QUINUCLIDIN-3-YL (2-(2-(4-FLUOROPHENYL)THIAZOL-4-YL)PROPAN-2-YL)CARBAMATE |
| Payment date | Validity (years) | Amount | |
| 2026-01-21 | 13 | 289.00 EUR |
| 2027-03-14 |